Head to head
Tesamorelin vs Sermorelin
Two compounds, one grading system.
On human evidence, Tesamorelin currently leads: fda approved versus well researched.
01
At a glance
TesamorelinFDA approved
Approved GHRH analogue for HIV-associated lipodystrophy — a narrow, real indication.
371publications
38RCTs
SermorelinWell researched
GHRH fragment with a long clinical history, once used diagnostically.
484publications
23RCTs
02
Side by side
| Attribute | Tesamorelin | Sermorelin |
|---|---|---|
| Goal | Metabolic & fat loss | Hormonal support |
| Evidence | FDA approved | Well researched |
| Publications | 371 | 484 |
| Randomised trials | 38 | 23 |
| Sport (WADA) | S2 — prohibited | S2 — prohibited |
| US compounding | — | — |
03
Claims vs data
Tesamorelin — claims vs data
| Reduces visceral fat in HIV-associated lipodystrophy | supported |
| Produces general fat loss in healthy adults | weak evidence |
| Improves cognition in ageing | weak evidence |
Sermorelin — claims vs data
| Stimulates natural growth-hormone release | supported |
| Reverses age-related decline | overreach |